Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis: etanercept, vascular function and endothelial progenitor cells in psoriasis
- PMID: 25617605
- PMCID: PMC9197324
- DOI: 10.1016/j.ijcard.2014.12.093
Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis: etanercept, vascular function and endothelial progenitor cells in psoriasis
Keywords: Arterial stiffness; Endothelial progenitor cells; Etanercept; Flow-mediated dilation; Psoriasis; TNF-alpha.
Conflict of interest statement
Conflict of interest
None of the authors have conflicts of interest to disclose.
Figures
References
-
- Gaeta M, Castelvecchio S, Ricci C, Pigatto P, Pellissero G, Cappato R, Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis, Int. J. Cardiol. 168 (3) (2013) 2282–2288. - PubMed
-
- Shaharyar S, Warraich H, McEvoy JW, Oni E, Ali SS, Karim A, et al., Subclinical cardiovascular disease in plaque psoriasis: association or causal link? Atherosclerosis 232 (1) (2014) 72–78. - PubMed
-
- Zhang C, Xu X, Potter BJ, Wang W, Kuo L, Michael L, et al., TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury, Arterioscler. Thromb. Vasc. Biol. 26 (3) (2006) 475–480. - PubMed
-
- Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al., Circulating endothelial progenitor cells and cardiovascular outcomes, N. Engl. J. Med. 353 (10) (2005) 999–1007. - PubMed
-
- Krause DS, Fackler MJ, Civin CI, May WS, CD34: structure, biology, and clinical utility [see comments], Blood 87 (1) (1996) 1–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical